WallStSmart

Ecolab Inc (ECL)vsNovo Nordisk A/S (NVO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novo Nordisk A/S generates 1892% more annual revenue ($327.80B vs $16.45B). NVO leads profitability with a 37.2% profit margin vs 12.8%. ECL appears more attractively valued with a PEG of 2.35. NVO earns a higher WallStSmart Score of 74/100 (B).

ECL

Buy

57

out of 100

Grade: C

Growth: 5.3Profit: 7.5Value: 4.3Quality: 5.8
Piotroski: 3/9Altman Z: 2.30

NVO

Strong Buy

74

out of 100

Grade: B

Growth: 9.3Profit: 10.0Value: 5.7Quality: 4.8
Piotroski: 3/9Altman Z: 2.13

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ECL2 strengths · Avg: 9.0/10
Market CapQuality
$72.46B9/10

Large-cap with strong market position

Return on EquityProfitability
22.4%9/10

Every $100 of equity generates 22 in profit

NVO6 strengths · Avg: 10.0/10
Market CapQuality
$202.85B10/10

Mega-cap, among the largest globally

P/E RatioValuation
10.6x10/10

Attractively priced relative to earnings

Return on EquityProfitability
71.4%10/10

Every $100 of equity generates 71 in profit

Profit MarginProfitability
37.2%10/10

Keeps 37 of every $100 in revenue as profit

Operating MarginProfitability
61.6%10/10

Strong operational efficiency at 61.6%

EPS GrowthGrowth
67.1%10/10

Earnings expanding 67.1% YoY

Areas to Watch

ECL3 concerns · Avg: 3.7/10
PEG RatioValuation
2.354/10

Expensive relative to growth rate

P/E RatioValuation
34.7x4/10

Premium valuation, high expectations priced in

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

NVO2 concerns · Avg: 2.5/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
4.882/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : ECL

The strongest argument for ECL centers on Market Cap, Return on Equity.

Bull Case : NVO

The strongest argument for NVO centers on Market Cap, P/E Ratio, Return on Equity. Profitability is solid with margins at 37.2% and operating margin at 61.6%. Revenue growth of 24.0% demonstrates continued momentum.

Bear Case : ECL

The primary concerns for ECL are PEG Ratio, P/E Ratio, Piotroski F-Score.

Bear Case : NVO

The primary concerns for NVO are Piotroski F-Score, PEG Ratio.

Key Dynamics to Monitor

ECL profiles as a value stock while NVO is a growth play — different risk/reward profiles.

ECL carries more volatility with a beta of 0.93 — expect wider price swings.

NVO is growing revenue faster at 24.0% — sustainability is the question.

NVO generates stronger free cash flow (12.0B), providing more financial flexibility.

Bottom Line

NVO scores higher overall (74/100 vs 57/100), backed by strong 37.2% margins and 24.0% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Ecolab Inc

BASIC MATERIALS · SPECIALTY CHEMICALS · USA

Ecolab Inc., headquartered in St. Paul, Minnesota, is an American corporation that develops and offers services, technology and systems that specialize in water treatment, purification, cleaning and hygiene in a wide variety of applications. It helps organizations both private market as well as public treat their water, not only for drinking directly, but also for use in food, healthcare, hospitality related safety and industry.

Novo Nordisk A/S

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.

Want to dig deeper into these stocks?